65,437 trials
Blepharospasm
Primary: Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater) — -0.8; 0.2 Points on a…
Vascular Access Complications · Cardiac Catheterization · Peripheral Vascular Disease
Primary: Participants With Successful Common Femoral Artery Cannulation, as Determined by Femoral Angiography — 408; 431 participants
Healthy Males
Primary: Serum Testosterone (T) — 0.43; 1.5; 3.7; 8.4 nmol/liter — p=<0.05
Pneumococcal Infections
Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (Mcg)/mL, 1 Month After the Infant Series. — 97.0; 97.9…
Comfort
Primary: Comfort — 90.2; 92.7; 84.5; 87.2 Units on a Scale
Depressive Disorder
Primary: Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8 — -10.4; -12.8; -12.5 scores on a scale — p=<0.001
Non Small Cell Lung Cancer
Primary: Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity — 15; 18 participants
Healthy
Primary: Cmax of Anastrozole(Maximum Observed Concentration of Drug Substance in Plasma) — 17.1; 17.8 ng/mL
Endometrial Cancer
Primary: Percent of Patients Estimated to be Progression-Free and Alive — 86; 76; 68 Percentage of Patients
Essential Hypertension
Primary: The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal…
Sleep Apnea, Obstructive · Tonsillectomy · Adenoidectomy
Primary: Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. — 21; 11 Participants
Hazardous Alcohol Consumption
Primary: Change in Weekly Alcohol Intake — -3.34; -1.21 standard drinks — p=0.0279
Colonoscopy
Primary: Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale — 89.6; 98.4 percentage of participants — p=0.038
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants With Adverse Events for Long Term Safety and Tolerability — 6; 222 Participants
Bacterial Pneumonia
Primary: Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations — 244; 233; 34; 58 participants